PDCD1 and esophageal squamous cell carcinoma: Our analyses showed that immune function of HBV+ ESCC patients was significantly enhanced after anti-PD-1 therapy, while HBV– patient had little change, which might be caused by prevailing differences in the immune microenvironment between HBV+ patients and HBV– patients.